Literature DB >> 19319858

Overview of gene silencing by RNA interference.

Daniel H Kim1, John J Rossi.   

Abstract

The potential of harnessing RNA interference (RNAi) for sequence-specific gene silencing has generated much excitement and progress in the field. Recent advances in RNAi technology suggest that RNAi-based approaches may soon become an effective therapeutic strategy against a myriad of diseases. This overview provides a brief description of important considerations when designing an RNAi-based method for gene silencing and therapeutic development: (a) mechanistic aspects of RNAi-mediated gene silencing in mammalian cells; (b) structural requirements for potent siRNA duplexes; (c) off-target effects and interferon responses; and (d) effective delivery of RNAi-inducing agents. Promising therapeutic applications of RNAi that are currently in the developmental pipeline are also described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319858     DOI: 10.1002/0471142700.nc1601s36

Source DB:  PubMed          Journal:  Curr Protoc Nucleic Acid Chem        ISSN: 1934-9270


  4 in total

Review 1.  Strategies for targeted nonviral delivery of siRNAs in vivo.

Authors:  Sang-Soo Kim; Himanshu Garg; Anjali Joshi; N Manjunath
Journal:  Trends Mol Med       Date:  2009-10-19       Impact factor: 11.951

2.  GATA-3 dose-dependent checkpoints in early T cell commitment.

Authors:  Deirdre D Scripture-Adams; Sagar S Damle; Long Li; Koorosh J Elihu; Shuyang Qin; Alexandra M Arias; Robert R Butler; Ameya Champhekar; Jingli A Zhang; Ellen V Rothenberg
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

Review 3.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

4.  Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.

Authors:  Hongran Yin; Gaofeng Xiong; Sijin Guo; Congcong Xu; Ren Xu; Peixuan Guo; Dan Shu
Journal:  Mol Ther       Date:  2019-04-25       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.